Results 41 to 50 of about 5,702,542 (372)
Current Problems in Cancer, 2009 Multiple myeloma is a typical bone marrow neoplasia of the elderly. On radiographs it is often difficult to detect the typical osteolyses in early stages or in regions where overlying structures hamper image analysis. Osteoporosis may be a sign of tumor infiltration, but it is difficult to distinguish from senile osteoporosis.
Andrea, Baur-Melnyk +1 more
openaire +4 more sources
Talquetamab in multiple myeloma
Haematologica, 2023 Initial results of the phase I trial of talquetamab, a bispecific antibody targeting GPRC5D and CD3, were reported in December of 2022 for the treatment of relapsed or refractory multiple myeloma in the fourth line or later setting.
Lawrence Liu, Amrita Krishnan
doaj +1 more source
Network modeling methods for precision medicine [PDF]
arXiv, 2021 We discuss in this survey several network modeling methods and their applicability to precision medicine. We review several network centrality methods (degree centrality, closeness centrality, eccentricity centrality, betweenness centrality, and eigenvector-based prestige) and two systems controllability methods (minimum dominating sets and network ...
arxiv
Journal of Clinical Oncology, 2015 PURPOSE The clinical outcome of multiple myeloma (MM) is heterogeneous. A simple and reliable tool is needed to stratify patients with MM. We combined the International Staging System (ISS) with chromosomal abnormalities (CA) detected by interphase ...
A. Palumbo +30 more
semanticscholar +1 more source
BJUI Compass, Volume 4, Issue 1, Page 44-58, January 2023., 2023 Abstract Metformin, the first line pharmacotherapy for type 2 diabetes has demonstrated favourable effects in prostate cancer (PCa) across a range of studies evaluating PCa patient outcomes amongst metformin users. However, a lack of rigorously conducted prospective studies has stalled clinical use in this setting.
Nan Fang Wang +3 more
wiley +1 more source
Annals of Oncology, 2010 Multiple myeloma (MM) is the second most common hematological malignancy, with an incidence of 6/100,000 in Europe. Interactions between myeloma cells and the microenvironment are essential for MM cell survival. Better knowledge of disease biology has led to the introduction of novel agents for the management of myeloma patients.
Dimopoulos, M.A., Terpos, E.
openaire +4 more sources
Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities
Frontiers in Oncology, 2021 Multiple myeloma (MM) is an incurable malignancy of plasma cells that grow within a permissive bone marrow microenvironment (BMM). The bone marrow milieu supports the malignant transformation both by promoting uncontrolled proliferation and resistance to
Leona Yamamoto +3 more
doaj +1 more source
Flexible Seamless 2-in-1 Design with Sample Size Adaptation [PDF]
, 2022 2-in-1 design (Chen et al. 2018) is becoming popular in oncology drug development, with the flexibility of using different endpoints at different decision time. Based on the observed interim data, sponsors choose either to seamlessly advance a small phase 2 trial to a full-scale confirmatory phase 3 trial with a pre-determined maximum sample size, or ...
arxiv +1 more source
Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma.
Journal of Clinical Oncology, 2020 PURPOSE Observation is the current standard of care for smoldering multiple myeloma. We hypothesized that early intervention with lenalidomide could delay progression to symptomatic multiple myeloma.
S. Lonial +16 more
semanticscholar +1 more source
Widespread intronic polyadenylation diversifies immune cell transcriptomes
Nature Communications, 2018 Recognition of intronic polyadenylation (IpA) signals can lead to expression of truncated proteins lacking C terminal domains. Analysis of 3ʹ -seq and RNA-seq shows that IpA is widespread in circulating immune cells, while multiple myeloma cells show ...
Irtisha Singh +8 more
doaj +1 more source